ICU Medical (NASDAQ:ICUI) Upgraded at StockNews.com

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research note issued to investors on Sunday morning.

Other analysts also recently issued reports about the stock. Raymond James decreased their price objective on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research report on Friday, May 9th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. Finally, KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $192.67.

ICU Medical Stock Down 2.2%

ICUI opened at $134.92 on Friday. ICU Medical has a 12 month low of $100.91 and a 12 month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market cap of $3.32 billion, a PE ratio of -29.52 and a beta of 0.87. The company has a 50 day moving average of $140.67 and a 200 day moving average of $153.48.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $599.49 million for the quarter, compared to analysts’ expectations of $574.15 million. During the same quarter in the prior year, the company earned $0.96 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. On average, sell-side analysts expect that ICU Medical will post 4.11 EPS for the current year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 5,556 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $138.65, for a total transaction of $770,339.40. Following the sale, the chief operating officer now directly owns 2,389 shares of the company’s stock, valued at $331,234.85. This trade represents a 69.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ben Sousa sold 2,000 shares of the firm’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $137.36, for a total value of $274,720.00. Following the sale, the insider now owns 479 shares in the company, valued at $65,795.44. This trade represents a 80.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,208 shares of company stock worth $2,926,969 over the last three months. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Institutional investors have recently bought and sold shares of the business. Harvest Fund Management Co. Ltd acquired a new position in shares of ICU Medical during the fourth quarter worth $33,000. Quarry LP grew its position in ICU Medical by 764.3% in the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 214 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical in the fourth quarter worth about $52,000. Venturi Wealth Management LLC lifted its position in shares of ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 206 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 300 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.